BML Capital Management’s Pardes Biosciences, Inc. Common Stock PRDS Stock Holding History

BML Capital Management’s Portfolio PRDS Stock Details PRDS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-3,791,633	Closed	-$6.86M	–	33
2023 Q2	$6.86M	Sell	3,791,633 -194,944	-5%	-$356K	6.17%	6
2023 Q1	$5.26M	Sell	3,986,577 -881,407	-18%	-$1.44M	4.55%	6
2022 Q4	$8.23M	Buy	+4,867,984	New	+$6.17M	7.86%	6

Other funds holding PRDS

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

BML Capital Management's PRDS Position: Q3 2023 in Review

BML Capital Management sold out of Pardes Biosciences, Inc. Common Stock (PRDS) in Q3 2023, closing a stake of 3,791,633 shares — an estimated $6.86M sold.

BML Capital Management first reported a position in PRDS in Q4 2022 and held it in 3 quarters. The position peaked at $8.23M in Q4 2022. 1 fund tracked by Wall St. Rank holds PRDS as of Q3 2023.

BML Capital Management reported no remaining Pardes Biosciences, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
BML Capital Management sold 3,791,633 Pardes Biosciences, Inc. Common Stock shares in Q3 2023, an estimated $6.86M.
BML Capital Management first reported a position in Pardes Biosciences, Inc. Common Stock in Q4 2022 and held it in 3 quarters.
BML Capital Management's Pardes Biosciences, Inc. Common Stock position peaked at $8.23M in Q4 2022.
1 fund tracked by Wall St. Rank held Pardes Biosciences, Inc. Common Stock as of Q3 2023.

Based on BML Capital Management's 13F filing for Q3 2023, filed 23 Oct 2023.